Skip to main content
Fig. 2 | Arthritis Research & Therapy

Fig. 2

From: Relationship of systemic type I interferon activity with clinical phenotypes, disease activity, and damage accrual in systemic lupus erythematosus in treatment-naive patients: a retrospective longitudinal analysis

Fig. 2

Associations between serum IFN activity and EULAR/ACR-2019 criteria domains in treatment-naive SLE patients. A Correlation between serum IFN activity and total score of the EULAR/ACR-2019 criteria was assessed in treatment-naive SLE patients (n = 40). B PCA was performed to examine the relationship between serum IFN activity and EULAR/ACR-2019 criteria domains. Each SLE patient is presented as a dot, with a gradation (gray to red) showing the level of serum IFN activity, and overlayed on the PCA. The arrow vector and length show the contribution ratio to the PCs. C Associations between serum IFN activity and each domain of the EULAR/ACR-2019 criteria were assessed by the Mann-Whitney test. p values < 0.05 were considered significant. Abs, antibodies; APL, anti-phospholipid; EULAR/ACR-2019 criteria, 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for SLE; IFN, type I interferon

Back to article page